Aurinia Pharma Files 8-K on Operations & Financial Condition

TL;DR

**Aurinia Pharma just dropped an 8-K on its financials and operations.**

AI Summary

Aurinia Pharmaceuticals Inc. filed an 8-K on January 5, 2024, reporting on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits.' This filing indicates that the company is providing an update on its financial performance and operational status, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into how the company is managing its finances and operations, directly impacting their investment's value.

Why It Matters

This filing provides a mandatory update on Aurinia Pharmaceuticals' financial health and operational activities, giving investors insight into the company's performance and stability.

Risk Assessment

Risk Level: medium — While a standard filing, the content of the 'Results of Operations and Financial Condition' could reveal positive or negative trends, impacting investor sentiment.

Analyst Insight

A smart investor would await the full details of the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' to assess Aurinia Pharmaceuticals Inc.'s current financial health before making any investment decisions.

Key Players & Entities

• Aurinia Pharmaceuticals Inc. (company) — the registrant filing the 8-K
• January 5, 2024 (date) — date of earliest event reported and filing date
• 001-36421 (string) — Commission File No.
• 98-1231763 (string) — IRS Employer Identification No.
• AUPH (string) — Trading Symbol on Nasdaq

FAQ

Filing Documents

• auph-20240105.htm (8-K) — 30KB
• auph4qpreannounceprjanuary.htm (EX-99.1) — 21KB
• 0001600620-24-000001.txt ( ) — 181KB
• auph-20240105.xsd (EX-101.SCH) — 2KB
• auph-20240105_lab.xml (EX-101.LAB) — 23KB
• auph-20240105_pre.xml (EX-101.PRE) — 12KB
• auph-20240105_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 5, 2024, Aurinia Pharmaceuticals Inc. (Aurinia or the Company) issued a press release announcing its preliminary unaudited fourth quarter and full-year 2023 net revenue results and providing preliminary net product revenue guidance for 2024. The Company also announced its preliminary unaudited amount of cash, cash equivalents, restricted cash and investments as of December 31, 2023. These amounts are preliminary and are subject to completion of financial closing procedures. As a result, these amounts may differ materially from the amounts that will be reflected in the Company's consolidated financial statements for the year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The preliminary financial data included in this Current Report on Form 8-K has been prepared by, and is the responsibility of, management. PricewaterhouseCoopers LLP has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The information in this Current Report on Form 8-K and the exhibit hereto are being furnished pursuant to this Item 2.02 and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K and the exhibit hereto, that is furnished pursuant to this Item 2.02 shall not be incorporated by reference in any of Aurinia's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in s

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 5, 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 4, 2024 AURINIA PHARMACEUTICALS INC. By: /s/ Joseph Miller Name: Joseph Miller Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR